Recombinant Adenovirus Vector Vaccine Studies

重组腺病毒载体疫苗研究

• 批准号: 8556082
• 负责人: Gary J Nabel
• 金额: $ 149.5万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8556082
• 关键词: Adenovirus Vector; Adenoviruses; Chad; Clinical Trials; Communicable Diseases; Cyclic GMP; DNA; Goals; HIV; HIV vaccine; Human; Immune response; Immune system; Immunity; Influenza; Pan Genus; Recombinants; Serotyping; Testing; Vaccines; Virus; defective adenoviral vector; vector; vector vaccine

Adenovirus vectors have shown promise for vaccines, but one key hurdle is preexisting immunity to these viruses in humans. The VRC has been investigating the use of priming with either DNA or adenovirus vaccines and the use of alternate adenoviral serotypes or modified adenoviral vectors to overcome prior immunity. During the past year, the VRC has evaluated chimpanzee adenovirus vectors (ChAd3 and ChAd63) to analyze their ability to induce an immune response as compared to Ad5 and in the presence of Ad5 seropostivity. Several of these vectors are being further tested to evaluate their potential use in clinical trials. Plans are in progress to produce cGMP lots of a ChAd HIV vaccine.

腺病毒载体已显示出用于疫苗的希望，但一个关键障碍是人类对这些病毒预先存在的免疫力。 VRC 一直在研究使用 DNA 或腺病毒疫苗引发，以及使用替代腺病毒血清型或修饰的腺病毒载体来克服先前的免疫力。 在过去的一年中，VRC 评估了黑猩猩腺病毒载体（ChAd3 和 ChAd63），以分析与 Ad5 相比以及在 Ad5 血清阳性存在的情况下它们诱导免疫反应的能力。 其中一些载体正在接受进一步测试，以评估它们在临床试验中的潜在用途。生产 cGMP 批次 ChAd HIV 疫苗的计划正在进行中。